rais forecast test
demand durat still unclear
lab core growth ahead cdd fall short
overal lcd better expect cdd fell bit short due clinic
trial site closur relat total rev grew y/i vs
our/street upsid larg due gain
acquisit vs estimate better organ growth vs
estimate see tabl pg lcd rev organ inclus
hit vs estimate our/street cdd
rev vs organ growth
vs estimate adj ep vs our/street est
lh withdrew guid headwind lcd routin test declin
end margin off-set molecular test
mdx lh expect increas mdx capac
serolog test capac ramp tests/day mid-may
bullish mdx see util ramp await vaccin
serolog demand harder assess given question test perform util
rais sale ep est
respect upsid potenti test util greater
expect longer term effort develop altern faster cheaper and/or
poc test option deliv central lab may well-posit
still much learn
rais estim po test tailwind
higher forecast rais po po still base
sotp analysi use multipl prior lcd multipl prior
cdd ev/ebitda estimate believ higher multipl lcd warrant given
lh key role test provid cdd multipl rais cro peer multipl
expans reiter neutral rate test tailwind seem mostli price
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
cdd covanc contract research
organ cro segment lh
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lh second-largest clinic laboratori
 intern invest acquisit
compani expand clinic diagnost
technolog offer better insul
growth rate lh also expand contract
research organ industri
acquisit covanc chiltern account
market share global
although see upsid potenti elev
lab consolid catalyz medicar
opportun monet lab data recent
multipl guidanc cut suggest visibl
limit said posit lh
abil weather headwind strong
industri trend drive higher growth
compani cro contract research
margin declin due impact
lcd side organ lab volum declin inclus headwind
ahead estimate street visibl alpha revenue
per requisit saw organ growth vs estimate driven better mix covid-
impact heavili weight toward routin test vs higher-pr esoter
test cdd compani saw signific impact clinic trial postpon
relat ttm book-to-bil vs estimate
lh gross profit declin gross margin
weak segment primarili due lcd ebita
ebita margin declin y/i primarili due
pama price cut higher labor cost cdd busi saw ebita
growth ebita margin y/i ex-
compani suspend share buy-back program announc varieti cost
tabl overview lh perform
po base sotp analysi assum multipl lh lcd lab
segment in-lin clinic lab histor three-year median forward multipl
multipl cdd cro segment slightli peer view
appropri given cdd posit cro industri ev/ebitda
upsid risk faster expect materi hospit lab consolid
trend smaller expect share loss contract retail clinic opportun
monet data lab cro busi significantli faster
cro growth margin improv
downsid risk greater expect price headwind lower expect test
volum growth market challeng relat competit execut risk
integr risk data privaci risk regulatori risk covanc drug develop
side lh like get much credit cdd well expect
given peer like get punish downsid sentiment wane
segment fall short
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
